Skip to main content

Joan Genescà Ferrer

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Joan Genescà Ferrer

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Chief Liver Unit.
Clinical director of Digestive Diseases.
Professor of Medicine of the UAB.

Projects

Estudio multicéntrico, aleatorizado, doble-ciego, controlado con placebo, sobre la eficacia del tratamiento con beta-bloqueantes para pevenir la descompensación de la cirrosis con hipertensión portal

IP: Joan Genescà Ferrer
Collaborators: Antonio González Fernández
Funding agency: Instituto de Salud Carlos III
Funding: 122815
Reference: EC08/00070
Duration: 01/01/2009 - 30/06/2013

Papel del sistema nervioso simpático en la génesis y mantenimiento de las alteraciones hemodinámicas (vasodilatación mesentérica) de la hipertensión portal.

IP: Joan Genescà Ferrer
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13500
Reference: PRED/IR-HUVH/13/2008
Duration: 01/01/2009 - 31/12/2012

Unitat de Recerca en Malalties Hepatobiliars

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Antonio González Fernández, Lluis Castells Fusté, Francisco Rodríguez Frias, Silvia Sauleda Oliveras, Lluís Palenzuela Díaz, Victor Manuel Vargas Blasco, Maria Buti Ferret, Josep Quer Sivila, Maria Nieves Martell Pérez-Alcalde, Rafael Esteban Mur, Juan Ignacio Esteban Mur, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 54080
Reference: 2009 SGR 383
Duration: 01/01/2010 - 30/04/2014

La inhibició de la transmissió adrenèrgica contribueix a la vasodilatació esplàcnica de la hipertensió portal

IP: Joan Genescà Ferrer
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 36000
Reference: POST-MIR/CAIX/02/07
Duration: 01/07/2007 - 30/06/2009

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Juan Pedro Barret Nerín

Juan Pedro Barret Nerín

Main researcher
Read more
Lasa Aranzasti, Amaia

Lasa Aranzasti, Amaia

Research technician
Genetics Medicine
Read more
Miquel Casas Brugué

Miquel Casas Brugué

Senior researcher
Psychiatry, Mental Health and Addictions
Read more
Guembe Zabaleta, Maria Blanca

Guembe Zabaleta, Maria Blanca

Predoctoral researcher
Basic, Translational and Clinical Pharmacy Research
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.